Dalazatide (TFA)

• Description:

  Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease[1][2][3].

• Product Name Alternative:

  ShK-186 (TFA)

• UNSPSC:

  12352209

• Target:

  Potassium Channel

• Type:

  Peptides

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/dalazatide-tfa.html

• Purity:

  99.92

• Solubility:

  DMSO : ≥ 100 mg/mL|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  CC[C@H] (C) [C@@H]1NC ([C@H] (CSSC[C@H] (NC ([C@@H] (NC (CNC (C2CSSC[C@@H]3NC ([C@H] (CCC (N) =O) NC ([C@H] (Cc4ccccc4) NC ([C@H] (C) NC ([C@@H] (NC ([C@H] (CSSC[C@H] (NC ([C@H] (Cc5ccccc5) NC ([C@H] (CO) NC ([C@H] (CC (C) C) NC ([C@H] (CCCNC (N) =N) NC ([C@H] (Cc6ccc (O) cc6) NC ([C@H] (CCCCN) NC ([C@H] (CCSC) NC ([C@H] (CO) NC ([C@H] (Cc7c[nH]cn7) NC ([C@H] (CCCCN) NC3=O) =O) =O) =O) =O) =O) =O) =O) =O) =O) =O) C (NC (CCCNC (N) =N) C (NC (CCCCN) C (N[C@@H] ([C@@H] (C) O) C (N2) =O) =O) =O) =O) NC ([C@H] (CCCNC (N) =N) NC ([C@H] (CO) NC ([C@H] (CCCCN) NC ([C@@H]8CCCN8C ([C@@H] (NC ([C@@H] (NC ([C@H] (CC (O) =O) NC1=O) =O) [C@@H] (C) O) =O) [C@@H] (C) CC) =O) =O) =O) =O) =O) =O) [C@@H] (C) O) =O) =O) =O) =O) =O) =O) [C@@H] (C) O) =O) C (N) =O) NC ([C@H] (CO) NC ([C@@] (N (C (C) =O) C ([C@@H] (N) Cc9ccc (OP (O) (O) =O) cc9) =O) (CCCNC (N) =N) OCCOCCN) =O) =O) =O.OC (C (F) (F) F) =O.[x]

• Molecular Formula:

  C184H296N57O55PS7.xC2HF3O2

• Molecular Weight:

  4442.10 (free acid)

• References & Citations:

  [1]Olsen C, et al. Dalazatide (ShK-186), a first-in-class peptide inhibitor of Kv1. 3 potassium channels, demonstrates safety, tolerability and proof of concept of efficacy in patients with active plaque psoriasis. J. Invest. Dermatol., 2016, 136 (8) .|[2]Stevens A M, et al. Thu0285 Dalazatide, an Inhibitor of the KV1. 3 Channel on Activated Effector Memory T Cells, Has Immunotherapy Potential in Systemic Lupus Erythematosus. 2016.|[3]Matheu MP, et al. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity. 2008 Oct 17;29 (4) :602-14.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

• Scientific Category:

  Peptides

• Clinical Information:

  Phase 1